Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 4, 2016, Pages 727-748

  Kalinowski, Danuta S ^a   Stefani, Christian ^a   Toyokuni, Shinya ^b   Ganz, Tomas ^c   Anderson, Gregory J ^d   Subramaniam, Nathan V ^d   Trinder, Debbie ^e   Olynyk, John K ^f,g,h   Chua, Anita ^e   Jansson, Patric J ^a   Sahni, Sumit ^a   Lane, Darius J R ^a   Merlot, Angelica M ^a   Kovacevic, Zaklina ^a   Huang, Michael L H ^a   Lee, C Soon ^i,j,k   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f FIONA STANLEY HOSPITAL   (Australia)

^g MURDOCH UNIVERSITY   (Australia)

^h CURTIN UNIVERSITY   (Australia)

ⁱ INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^j UNIVERSITY OF WESTERN SYDNEY   (Australia)

^k LIVERPOOL HOSPITAL   (Australia)

more..

Author keywords

Bis(thiosemicarbazones); Cancer; Copper; Dp44mT; DpC; Iron; Thiosemicarbazones

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; BENZOYLPYRIDINE THIOSEMICARBAZONE DERIVATIVE; BIS(THIOSEMICARBAZONE) DERIVATIVE; COPPER; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE DERIVATIVE; GLYOXAL BIS(N4 METHYL 3 THIOSEMICARBAZONE); HEPCIDIN; IRON; METAL; METAL COMPLEX; METAL ION; REACTIVE OXYGEN METABOLITE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; CHELATING AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; COPPER METABOLISM; DNA SYNTHESIS; DRUG TARGETING; GENE EXPRESSION; HUMAN; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LIGAND BINDING; METABOLISM; METASTASIS; METASTASIS INHIBITION; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SUPPRESSOR GENE; ANIMAL; DRUG DEVELOPMENT; NEOPLASMS; PATHOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; COPPER; DRUG DISCOVERY; HUMANS; IRON; METALS; NEOPLASMS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84957990154     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.01.026     Document Type: Review

References (331)

1. Buss J.L., Greene B.T., Turner J., Torti F.M., Torti S.V. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 2004, 4:1623-1635.
2. Kalinowski D.S., Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
3. Denoyer D., Masaldan S., La Fontaine S., Cater M.A. Targeting copper in cancer therapy: 'Copper that Cancer'. Metallomics 2015, 7:1459-1476.
4. Cai L., Li X.K., Song Y., Cherian M.G. Essentiality, toxicology and chelation therapy of zinc and copper. Curr. Med. Chem. 2005, 12:2753-2763.
5. Nyholm S., Mann G.J., Johansson A.G., Bergeron R.J., Graslund A., Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 1993, 268:26200-26205.
6. Thelander L., Graslund A., Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 1983, 110:859-865.
7. Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 1979, 48:133-158.
8. Tapiero H., Townsend D.M., Tew K.D. Trace elements in human physiology and pathology: copper. Biomed. Pharmacother. 2003, 57:386-398.
9. Finney L., Mandava S., Ursos L., Zhang W., Rodi D., Vogt S., Legnini D., Maser J., Ikpatt F., Olopade O.I., Glesne D. X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2247-2252.
10. Jomova K., Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011, 283:65-87.
11. Yu Y., Kalinowski D.S., Kovacevic Z., Siafakas A.R., Jansson P.J., Stefani C., Lovejoy D.B., Sharpe P.C., Bernhardt P.V., Richardson D.R. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J. Med. Chem. 2009, 52:5271-5294.
12. De Domenico I., McVey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol. Cell Biol. 2008, 9:72-81.
13. Lane D.J., Merlot A.M., Huang M.L., Bae D.H., Jansson P.J., Sahni S., Kalinowski D.S., Richardson D.R. Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochim. Biophys. Acta 2015, 1853:1130-1144.
14. Hentze M.W., Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8175-8182.
15. Grubman A., White A.R. Copper as a key regulator of cell signalling pathways. Expert Rev. Mol. Med. 2014, 16.
16. Turski M.L., Thiele D.J. New roles for copper metabolism in cell proliferation, signaling, and disease. J. Biol. Chem. 2009, 284:717-721.
17. Torti S.V., Torti F.M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 2013, 13:342-355.
18. Kuo H.W., Chen S.F., Wu C.C., Chen D.R., Lee J.H. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol. Trace Elem. Res. 2002, 89:1-11.
19. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009, 100:9-16.
20. Margalioth E.J., Schenker J.G., Chevion M. Copper and zinc levels in normal and malignant tissues. Cancer 1983, 52:868-872.
21. Merlot A.M., Kalinowski D.S., Richardson D.R. Novel chelators for cancer treatment: where are we now?. Antioxid. Redox Signal. 2013, 18:973-1006.
22. Dunn L.L., Suryo Rahmanto Y., Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007, 17:93-100.
23. Muckenthaler M.U., Galy B., Hentze M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 2008, 28:197-213.
24. Lawen A., Lane D.J. Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid. Redox Signal. 2013, 18:2473-2507.
25. Steinbicker A.U., Muckenthaler M.U. Out of balance-systemic iron homeostasis in iron-related disorders. Nutrients 2013, 5:3034-3061.
26. Arosio P., Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 2010, 1800:783-792.
27. Lill R. Function and biogenesis of iron-sulphur proteins. Nature 2009, 460:831-838.
28. Rouault T.A. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis. Model. Mech. 2012, 5:155-164.
29. Philpott C.C., Ryu M.S. Special delivery: distributing iron in the cytosol of mammalian cells. Front. Pharmacol. 2014, 5:173.
30. Richardson D.R., Lane D.J., Becker E.M., Huang M.L., Whitnall M., Suryo Rahmanto Y., Sheftel A.D., Ponka P. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10775-10782.
31. Silva B., Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim. Biophys. Acta 2015, 1852:1347-1359.
32. Gulec S., Anderson G.J., Collins J.F. Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 307:G397-G409.
33. Anderson G.J., Darshan D., Wilkins S.J., Frazer D.M. Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals 2007, 20:665-674.
34. Sharp P.A. Intestinal iron absorption: regulation by dietary & systemic factors. Int. J. Vitam. Nutr. Res. 2010, 80:231-242.
35. Laftah A.H., Latunde-Dada G.O., Fakih S., Hider R.C., Simpson R.J., McKie A.T. Haem and folate transport by proton-coupled folate transporter/haem carrier protein 1 (SLC46A1). Br. J. Nutr. 2009, 101:1150-1156.
36. Worthington M.T., Cohn S.M., Miller S.K., Luo R.Q., Berg C.L. Characterization of a human plasma membrane heme transporter in intestinal and hepatocyte cell lines. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G1172-G1177.
37. Inoue K., Nakai Y., Ueda S., Kamigaso S., Ohta K.Y., Hatakeyama M., Hayashi Y., Otagiri M., Yuasa H. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G660-G668.
38. Wolf G. Identification of proton-coupled high-affinity human intestinal folate transporter mutated in human hereditary familial folate malabsorption. Nutr. Rev. 2007, 65:554-557.
39. Dawson R.B., Rafal S., Weintraub L.R. Absorption of hemoglobin iron: the role of xanthine oxidase in the intestinal heme-splitting reaction. Blood 1970, 35:94-103.
40. Pollack S., Kaufman R., Crosby W.H., Butkiewicz J.E. Reducing agents and absorption of iron. Nature 1963, 199:384.
41. McKie A.T., Barrow D., Latunde-Dada G.O., Rolfs A., Sager G., Mudaly E., Mudaly M., Richardson C., Barlow D., Bomford A., Peters T.J., Raja K.B., Shirali S., Hediger M.A., Farzaneh F., Simpson R.J. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001, 291:1755-1759.
42. Lane D.J., Bae D.H., Merlot A.M., Sahni S., Richardson D.R. Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients 2015, 7:2274-2296.
43. Ohgami R.S., Campagna D.R., Greer E.L., Antiochos B., McDonald A., Chen J., Sharp J.J., Fujiwara Y., Barker J.E., Fleming M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 2005, 37:1264-1269.
44. May J.M., Qu Z.C., Mendiratta S. Role of ascorbic acid in transferrin-independent reduction and uptake of iron by U-937 cells. Biochem. Pharmacol. 1999, 57:1275-1282.
45. Lane D.J., Lawen A. Non-transferrin iron reduction and uptake are regulated by transmembrane ascorbate cycling in K562 cells. J. Biol. Chem. 2008, 283:12701-12708.
46. Lane D.J., Robinson S.R., Czerwinska H., Bishop G.M., Lawen A. Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. Biochem. J. 2010, 432:123-132.
47. Fleming M.D., Trenor C.C., Su M.A., Foernzler D., Beier D.R., Dietrich W.F., Andrews N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 1997, 16:383-386.
48. Liuzzi J.P., Aydemir F., Nam H., Knutson M.D., Cousins R.J. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13612-13617.
49. Donovan A., Lima C.A., Pinkus J.L., Pinkus G.S., Zon L.I., Robine S., Andrews N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005, 1:191-200.
50. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 2000, 5:299-309.
51. Chen H., Attieh Z.K., Su T., Syed B.A., Gao H., Alaeddine R.M., Fox T.C., Usta J., Naylor C.E., Evans R.W., McKie A.T., Anderson G.J., Vulpe C.D. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 2004, 103:3933-3939.
52. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., Gitschier J., Anderson G.J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 1999, 21:195-199.
53. Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997, 1331:1-40.
54. Hentze M.W., Muckenthaler M.U., Galy B., Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010, 142:24-38.
55. Lane D.J., Richardson D.R. Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline. Biochem. J. 2014, 462:e1-e3.
56. Lane D.J., Chikhani S., Richardson V., Richardson D.R. Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochim. Biophys. Acta 2013, 1833:1527-1541.
57. Escobar A., Gaete V., Nunez M.T. Effect of ascorbate in the reduction of transferrin-associated iron in endocytic vesicles. J. Bioenerg. Biomembr. 1992, 24:227-233.
58. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997, 388:482-488.
59. Jenkitkasemwong S., Wang C.Y., Mackenzie B., Knutson M.D. Physiologic implications of metal-ion transport by ZIP14 and ZIP8. Biometals 2012, 25:643-655.
60. Trinder D., Baker E. Transferrin receptor 2: a new molecule in iron metabolism. Int. J. Biochem. Cell Biol. 2003, 35:292-296.
61. Richardson D.R., Baker E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1990, 1053:1-12.
62. Trinder D., Zak O., Aisen P. Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 1996, 23:1512-1520.
63. Richardson D.R., Baker E. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J. Cell. Physiol. 1994, 161:160-168.
64. Trinder D., Morgan E., Baker E. The mechanisms of iron uptake by fetal rat hepatocytes in culture. Hepatology 1986, 6:852-858.
65. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
66. Grootveld M., Bell J.D., Halliwell B., Aruoma O.I., Bomford A., Sadler P.J. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 1989, 264:4417-4422.
67. Richardson D.R., Chua A.C., Baker E. Activation of an iron uptake mechanism from transferrin in hepatocytes by small-molecular-weight iron complexes: implications for the pathogenesis of iron-overload disease. J. Lab. Clin. Med. 1999, 133:144-151.
68. Richardson D.R., Ponka P. Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim. Biophys. Acta 1995, 1269:105-114.
69. Ohgami R.S., Campagna D.R., McDonald A., Fleming M.D. The Steap proteins are metalloreductases. Blood 2006, 108:1388-1394.
70. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood 1977, 50:433-439.
71. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res. 2003, 531:81-92.
72. Hider R.C., Kong X.L. Glutathione: a key component of the cytoplasmic labile iron pool. Biometals 2011, 24:1179-1187.
73. Watts R.N., Richardson D.R. Nitrogen monoxide (NO) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells. J. Biol. Chem. 2001, 276:4724-4732.
74. Richardson D.R., Ponka P., Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 1996, 87:3477-3488.
75. Sheftel A.D., Zhang A.S., Brown C., Shirihai O.S., Ponka P. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 2007, 110:125-132.
76. Lutsenko S. Human copper homeostasis: a network of interconnected pathways. Curr. Opin. Chem. Biol. 2010, 14:211-217.
77. Richardson D.R., Suryo Rahmanto Y. Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta. Biochem. J. 2007, 402:e1-e3.
78. Nandal A., Ruiz J.C., Subramanian P., Ghimire-Rijal S., Sinnamon R.A., Stemmler T.L., Bruick R.K., Philpott C.C. Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2. Cell Metab. 2011, 14:647-657.
79. Leidgens S., Bullough K.Z., Shi H., Li F., Shakoury-Elizeh M., Yabe T., Subramanian P., Hsu E., Natarajan N., Nandal A., Stemmler T.L., Philpott C.C. Each member of the poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin. J. Biol. Chem. 2013, 288:17791-17802.
80. Zhang A.S., Sheftel A.D., Ponka P. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 2005, 105:368-375.
81. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997, 89:1-25.
82. Chasteen N.D., Harrison P.M. Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 1999, 126:182-194.
83. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1996, 1275:161-203.
84. Kurz T., Terman A., Brunk U.T. Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. Arch. Biochem. Biophys. 2007, 462:220-230.
85. Zhang Y., Mikhael M., Xu D., Li Y., Soe-Lin S., Ning B., Li W., Nie G., Zhao Y., Ponka P. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid. Redox Signal. 2010, 13:999-1009.
86. Mancias J.D., Wang X., Gygi S.P., Harper J.W., Kimmelman A.C. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014, 509:105-109.
87. Kurz T., Terman A., Gustafsson B., Brunk U.T. Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 2008, 129:389-406.
88. Drysdale J., Arosio P., Invernizzi R., Cazzola M., Volz A., Corsi B., Biasiotto G., Levi S. Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol. Dis. 2002, 29:376-383.
89. Levi S., Corsi B., Bosisio M., Invernizzi R., Volz A., Sanford D., Arosio P., Drysdale J. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 2001, 276:24437-24440.
90. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., Rolandi V., Biasiotto G., Drysdale J., Arosio P. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003, 101:1996-2000.
91. Corsi B., Cozzi A., Arosio P., Drysdale J., Santambrogio P., Campanella A., Biasiotto G., Albertini A., Levi S. Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J. Biol. Chem. 2002, 277:22430-22437.
92. Nie G., Chen G., Sheftel A.D., Pantopoulos K., Ponka P. In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood 2006, 108:2428-2434.
93. Huang M.L., Becker E.M., Whitnall M., Suryo Rahmanto Y., Ponka P., Richardson D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16381-16386.
94. Whitnall M., Suryo Rahmanto Y., Huang M.L., Saletta F., Lok H.C., Gutierrez L., Lazaro F.J., Fleming A.J., Pierre T.G.St, Mikhael M.R., Ponka P., Richardson D.R. Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20590-20595.
95. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
96. Rouault T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2006, 2:406-414.
97. Guo B., Phillips J.D., Yu Y., Leibold E.A. Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J. Biol. Chem. 1995, 270:21645-21651.
98. Vashisht A.A., Zumbrennen K.B., Huang X., Powers D.N., Durazo A., Sun D., Bhaskaran N., Persson A., Uhlen M., Sangfelt O., Spruck C., Leibold E.A., Wohlschlegel J.A. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 2009, 326:718-721.
99. Salahudeen A.A., Thompson J.W., Ruiz J.C., Ma H.W., Kinch L.N., Li Q., Grishin N.V., Bruick R.K. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science 2009, 326:722-726.
100. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
101. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276:7806-7810.
102. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000, 480:147-150.
103. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr. Blood Cancer 2006, 46:554-557.
104. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim. Biophys. Acta 2009, 1790:682-693.
105. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL-mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004, 113:1271-1276.
106. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
107. Theurl I., Schroll A., Sonnweber T., Nairz M., Theurl M., Willenbacher W., Eller K., Wolf D., Seifert M., Sun C.C., Babitt J.L., Hong C.C., Menhall T., Gearing P., Lin H.Y., Weiss G. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118:4977-4984.
108. Huang M.L., Austin C.J., Sari M.A., Rahmanto Y.S., Ponka P., Vyoral D., Richardson D.R. Hepcidin bound to alpha2-macroglobulin reduces ferroportin-expression and enhances its activity at reducing serum iron levels. J. Biol. Chem. 2013, 288:25450-25465.
109. Peslova G., Petrak J., Kuzelova K., Hrdy I., Halada P., Kuchel P.W., Soe-Lin S., Ponka P., Sutak R., Becker E., Huang M.L., Suryo Rahmanto Y., Richardson D.R., Vyoral D. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009, 113:6225-6236.
110. Pandur E., Nagy J., Poor V.S., Sarnyai A., Huszar A., Miseta A., Sipos K. Alpha-antitrypsin binds preprohepcidin intracellularly and prohepcidin in the serum. FEBS J. 2009, 276:2012-2021.
111. Borth W. Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992, 6:3345-3353.
112. La Fontaine S., Ackland M.L., Mercer J.F. Mammalian copper-transporting P-type ATPases, ATP7A and ATP7B: emerging roles. Int. J. Biochem. Cell Biol. 2010, 42:206-209.
113. Crampton R.F., Matthews D.M., Poisner R. Observations on the mechanism of absorption of copper by the small intestine. J. Physiol. 1965, 178:111-126.
114. Lonnerdal B. Bioavailability of copper. Am. J. Clin. Nutr. 1996, 63:821S-829S.
115. Linder M.C., Hazegh-Azam M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 1996, 63:797S-811S.
116. Harris E.D. Cellular copper transport and metabolism. Annu. Rev. Nutr. 2000, 20:291-310.
117. Lee J., Petris M.J., Thiele D.J. Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. identification of a Ctr1-independent copper transport system. J. Biol. Chem. 2002, 277:40253-40259.
118. 1+ transporter of intestinal cells. Am. J. Physiol. Cell Physiol. 2003, 284:C1525-C1530.
119. Arredondo M., Mendiburo M.J., Flores S., Singleton S.T., Garrick M.D. Mouse divalent metal transporter 1 is a copper transporter in HEK293 cells. Biometals 2014, 27:115-123.
120. Blair B.G., Larson C.A., Safaei R., Howell S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 2009, 15:4312-4321.
121. Wang T., Guo Z. Copper in medicine: homeostasis, chelation therapy and antitumor drug design. Curr. Med. Chem. 2006, 13:525-537.
122. Wee N.K., Weinstein D.C., Fraser S.T., Assinder S.J. The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease. Int. J. Biochem. Cell Biol. 2013, 45:960-963.
123. Kidane T.Z., Farhad R., Lee K.J., Santos A., Russo E., Linder M.C. Uptake of copper from plasma proteins in cells where expression of CTR1 has been modulated. Biometals 2012, 25:697-709.
124. Knutson M.D. Steap proteins: implications for iron and copper metabolism. Nutr. Rev. 2007, 65:335-340.
125. Kim B.E., Nevitt T., Thiele D.J. Mechanisms for copper acquisition, distribution and regulation. Nat. Chem. Biol. 2008, 4:176-185.
126. Valko M., Morris H., Cronin M.T. Metals, toxicity and oxidative stress. Curr. Med. Chem. 2005, 12:1161-1208.
127. Markossian K.A., Kurganov B.I. Copper chaperones, intracellular copper trafficking proteins. function, structure, and mechanism of action. Biochemical 2003, 68:827-837.
128. Richardson D.R. Role of ceruloplasmin and ascorbate in cellular iron release. J. Lab. Clin. Med. 1999, 134:454-465.
129. Arredondo M., Nunez M.T. Iron and copper metabolism. Mol. Asp. Med. 2005, 26:313-327.
130. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002, 22:439-458.
131. Lutsenko S., Barnes N.L., Bartee M.Y., Dmitriev O.Y. Function and regulation of human copper-transporting ATPases. Physiol. Rev. 2007, 87:1011-1046.
132. Nyasae L., Bustos R., Braiterman L., Eipper B., Hubbard A. Dynamics of endogenous ATP7A (Menkes protein) in intestinal epithelial cells: copper-dependent redistribution between two intracellular sites. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1181-G1194.
133. Prohaska J.R. Role of copper transporters in copper homeostasis. Am. J. Clin. Nutr. 2008, 88:826S-829S.
134. Leary S.C., Kaufman B.A., Pellecchia G., Guercin G.H., Mattman A., Jaksch M., Shoubridge E.A. Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum. Mol. Genet. 2004, 13:1839-1848.
135. Yang L., McRae R., Henary M.M., Patel R., Lai B., Vogt S., Fahrni C.J. Imaging of the intracellular topography of copper with a fluorescent sensor and by synchrotron x-ray fluorescence microscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11179-11184.
136. van den Berghe P.V., Folmer D.E., Malingre H.E., van Beurden E., Klomp A.E., van de Sluis B., Merkx M., Berger R., Klomp L.W. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 2007, 407:49-59.
137. Jansson P.J., Yamagishi T., Arvind A., Seebacher N., Gutierrez E., Stacy A., Maleki S., Sharp D., Sahni S., Richardson D.R. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J. Biol. Chem. 2015, 290:9588-9603.
138. Lovejoy D.B., Jansson P.J., Brunk U.T., Wong J., Ponka P., Richardson D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 2011, 71:5871-5880.
139. Cobine P.A., Ojeda L.D., Rigby K.M., Winge D.R. Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix. J. Biol. Chem. 2004, 279:14447-14455.
140. Rees E.M., Thiele D.J. Identification of a vacuole-associated metalloreductase and its role in Ctr2-mediated intracellular copper mobilization. J. Biol. Chem. 2007, 282:21629-21638.
141. Moller L.B., Petersen C., Lund C., Horn N. Characterization of the hCTR1 gene: genomic organization, functional expression, and identification of a highly homologous processed gene. Gene 2000, 257:13-22.
142. Lenartowicz M., Krzeptowski W. Structure and function of ATP7A and ATP7B proteins-Cu-transporting ATPases. Postepy Biochem. 2010, 56:317-327.
143. Kaler S.G. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat. Rev. Neurol. 2011, 7:15-29.
144. La Fontaine S., Mercer J.F. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch. Biochem. Biophys. 2007, 463:149-167.
145. Telianidis J., Hung Y.H., Materia S., Fontaine S.L. Role of the P-type ATPases, ATP7A and ATP7B in brain copper homeostasis. Front. Aging Neurosci. 2013, 5:44.
146. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
147. Jungwirth U., Kowol C.R., Keppler B.K., Hartinger C.G., Berger W., Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid. Redox Signal. 2011, 15:1085-1127.
148. Lieu P.T., Heiskala M., Peterson P.A., Yang Y. The roles of iron in health and disease. Mol. Asp. Med. 2001, 22:1-87.
149. Koppenol W.H. The Haber-Weiss cycle-70 years later. Redox Rep. 2001, 6:229-234.
150. Theophanides T., Anastassopoulou J. Copper and carcinogenesis. Crit. Rev. Oncol. Hematol. 2002, 42:57-64.
151. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3:205-214.
152. Dizdaroglu M., Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic. Res. 2012, 46:382-419.
153. Stadtman E.R. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic. Biol. Med. 1990, 9:315-325.
154. Alper G., Narayanan V. Friedreich's ataxia. Pediatr. Neurol. 2003, 28:335-341.
155. Schrier S.L., Centis F., Verneris M., Ma L., Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep. 2003, 8:241-245.
156. Wong A., Yang J., Cavadini P., Gellera C., Lonnerdal B., Taroni F., Cortopassi G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 1999, 8:425-430.
157. Bull P.C., Cox D.W. Wilson disease and Menkes disease: new handles on heavy-metal transport. Trends Genet. 1994, 10:246-252.
158. Jiang L., Akatsuka S., Nagai H., Chew S.H., Ohara H., Okazaki Y., Yamashita Y., Yoshikawa Y., Yasui H., Ikuta K., Sasaki K., Kohgo Y., Hirano S., Shinohara Y., Kohyama N., Takahashi T., Toyokuni S. Iron overload signature in chrysotile-induced malignant mesothelioma. J. Pathol. 2012, 228:366-377.
159. Wu T., Sempos C.T., Freudenheim J.L., Muti P., Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann. Epidemiol. 2004, 14:195-201.
160. Knekt P., Reunanen A., Takkunen H., Aromaa A., Heliovaara M., Hakulinen T. Body iron stores and risk of cancer. Int. J. Cancer 1994, 56:379-382.
161. Nelson R.L. Iron and colorectal cancer risk: human studies. Nutr. Rev. 2001, 59:140-148.
162. Akatsuka S., Yamashita Y., Ohara H., Liu Y.T., Izumiya M., Abe K., Ochiai M., Jiang L., Nagai H., Okazaki Y., Murakami H., Sekido Y., Arai E., Kanai Y., Hino O., Takahashi T., Nakagama H., Toyokuni S. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One 2012, 7.
163. Chua A.C., Klopcic B.R., Ho D.S., Fu S.K., Forrest C.H., Croft K.D., Olynyk J.K., Lawrance I.C., Trinder D. Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice. PLoS One 2013, 8.
164. Norat T., Lukanova A., Ferrari P., Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int. J. Cancer 2002, 98:241-256.
165. van Asperen I.A., Feskens E.J., Bowles C.H., Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int. J. Epidemiol. 1995, 24:665-670.
166. Edgren G., Reilly M., Hjalgrim H., Tran T.N., Rostgaard K., Adami J., Titlestad K., Shanwell A., Melbye M., Nyren O. Donation frequency, iron loss, and risk of cancer among blood donors. J. Natl. Cancer Inst. 2008, 100:572-579.
167. Rienhoff H.Y. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 2008, 358:2294-2295.
168. Bradbear R.A., Bain C., Siskind V., Schofield F.D., Webb S., Axelsen E.M., Halliday J.W., Bassett M.L., Powell L.W. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J. Natl. Cancer Inst. 1985, 75:81-84.
169. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., Lindgren S., Loof L., Stal P., Wallerstedt S., Almer S., Sandberg-Gertzen H., Askling J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125:1733-1741.
170. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., Kawano Y., Takahashi S., Takahashi M., Sato Y., Takayama T., Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007, 42:830-836.
171. Kwok J.C., Richardson D.R. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit. Rev. Oncol. Hematol. 2002, 42:65-78.
172. Le N.T., Richardson D.R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta 2002, 1603:31-46.
173. Daniels T.R., Bernabeu E., Rodriguez J.A., Patel S., Kozman M., Chiappetta D.A., Holler E., Ljubimova J.Y., Helguera G., Penichet M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820:291-317.
174. Boult J., Roberts K., Brookes M.J., Hughes S., Bury J.P., Cross S.S., Anderson G.J., Spychal R., Iqbal T., Tselepis C. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin. Cancer Res. 2008, 14:379-387.
175. Prutki M., Poljak-Blazi M., Jakopovic M., Tomas D., Stipancic I., Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett. 2006, 238:188-196.
176. Gomes I.M., Maia C.J., Santos C.R. STEAP proteins: from structure to applications in cancer therapy. Mol. Cancer Res. 2012, 10:573-587.
177. Zhang S., Chen Y., Guo W., Yuan L., Zhang D., Xu Y., Nemeth E., Ganz T., Liu S. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell. Signal. 2014, 26:2539-2550.
178. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
179. Rivera S., Liu L., Nemeth E., Gabayan V., Sorensen O.E., Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005, 105:1797-1802.
180. Chua A.C., Graham R.M., Trinder D., Olynyk J.K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007, 44:413-459.
181. Pinnix Z.K., Miller L.D., Wang W., D'Agostino R., Kute T., Willingham M.C., Hatcher H., Tesfay L., Sui G., Di X., Torti S.V., Torti F.M. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2010, 2. (43ra56).
182. Shpyleva S.I., Tryndyak V.P., Kovalchuk O., Starlard-Davenport A., Chekhun V.F., Beland F.A., Pogribny I.P. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res. Treat. 2011, 126:63-71.
183. Tan M.G., Kumarasinghe M.P., Wang S.M., Ooi L.L., Aw S.E., Hui K.M. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp. Biol. Med. 2009, 234:693-702.
184. Milman N., Pedersen L.M. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer. Oncol. Rep. 2002, 9:193-198.
185. Lorenzi M., Lorenzi B., Vernillo R. Serum ferritin in colorectal cancer patients and its prognostic evaluation. Int. J. Biol. Markers 2006, 21:235-241.
186. Yang D.C., Wang F., Elliott R.L., Head J.F. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res. 2001, 21:541-549.
187. Radulescu S., Brookes M.J., Salgueiro P., Ridgway R.A., McGhee E., Anderson K., Ford S.J., Stones D.H., Iqbal T.H., Tselepis C., Sansom O.J. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep. 2012, 2:270-282.
188. Wu K.J., Polack A., Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999, 283:676-679.
189. Funauchi Y., Tanikawa C., Yi Lo P.H., Mori J., Daigo Y., Takano A., Miyagi Y., Okawa A., Nakamura Y., Matsuda K. Regulation of iron homeostasis by the p53-ISCU pathway. Sci. Rep. 2015, 5:16497.
190. Coffman L.G., Parsonage D., D'Agostino R., Torti F.M., Torti S.V. Regulatory effects of ferritin on angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:570-575.
191. Richardson D.R., Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997, 89:3025-3038.
192. Gao J., Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98:842-850.
193. Kolberg M., Strand K.R., Graff P., Andersson K.K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 2004, 1699:1-34.
194. Elford H.L., Freese M., Passamani E., Morris H.P. Ribonucleotide reductase and cell proliferation. I. variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem. 1970, 245:5228-5233.
195. Liang S.X., Richardson D.R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 2003, 24:1601-1614.
196. Yu Y., Kovacevic Z., Richardson D.R. Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6:1982-1994.
197. Le N.T., Richardson D.R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation. Blood 2004, 104:2967-2975.
198. Masuda K., Ono M., Okamoto M., Morikawa W., Otsubo M., Migita T., Tsuneyoshi M., Okuda H., Shuin T., Naito S., Kuwano M. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Int. J. Cancer 2003, 105:803-810.
199. Lane D.J., Saletta F., Suryo Rahmanto Y., Kovacevic Z., Richardson D.R. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One 2013, 8.
200. Hwang J., Kim H.S., Kang B.S., Kim D.H., Ryoo Z.Y., Choi S.U., Lee S. RGS19 converts iron deprivation stress into a growth-inhibitory signal. Biochem. Biophys. Res. Commun. 2015, 464:168-175.
201. Kvietikova I., Wenger R.H., Marti H.H., Gassmann M. The transcription factors ATF-and CREB-bind constitutively to the hypoxia-inducible factor-(HIF-1) DNA recognition site. Nucleic Acids Res. 1995, 23:4542-4550.
202. Bandyopadhyay S., Pai S.K., Gross S.C., Hirota S., Hosobe S., Miura K., Saito K., Commes T., Hayashi S., Watabe M., Watabe K. The Drg-gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003, 63:1731-1736.
203. Bandyopadhyay S., Pai S.K., Hirota S., Hosobe S., Takano Y., Saito K., Piquemal D., Commes T., Watabe M., Gross S.C., Wang Y., Ran S., Watabe K. Role of the putative tumor metastasis suppressor gene Drg-in breast cancer progression. Oncogene 2004, 23:5675-5681.
204. Shah M.A., Kemeny N., Hummer A., Drobnjak M., Motwani M., Cordon-Cardo C., Gonen M., Schwartz G.K. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin. Cancer Res. 2005, 11:3296-3302.
205. Blaes J., Weiler M., Sahm F., Hentschel B., Osswald M., Czabanka M., Thome C.M., Schliesser M.G., Pusch S., Luger S., Winkler F., Radbruch A., Jugold M., Simon M., Steinbach J.P., Schackert G., Tatagiba M., Westphal M., Tonn J.C., Gramatzki D., Pietsch T., Hartmann C., Glimm H., Vajkoczy P., von Deimling A., Platten M., Weller M., Wick W. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J. Neuro-Oncol. 2014, 117:25-32.
206. Matsushita K., Uchida K., Saigusa S., Ide S., Hashimoto K., Koike Y., Otake K., Inoue M., Tanaka K., Kusunoki M. Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients. Pediatr. Surg. Int. 2013, 29:363-368.
207. Dos Santos M., da Cunha Mercante A.M., Nunes F.D., Leopoldino A.M., de Carvalho M.B., Gazito D., Lopez R.V., Chiappini P.B., de Carvalho Neto P.B., Fukuyama E.E., Tajara E.H., Louro I.D., da Silva A.M. Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma. Mol. Biol. Rep. 2012, 39:10157-10165.
208. Hosoi F., Izumi H., Kawahara A., Murakami Y., Kinoshita H., Kage M., Nishio K., Kohno K., Kuwano M., Ono M. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res. 2009, 69:4983-4991.
209. Wangpu X., Yang X., Zhao J., Lu J., Guan S., Kovacevic Z., Liu W., Mi L., Jin R., Sun J., Yue F., Ma J., Lu A., Richardson D.R., Wang L., Zheng M. The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear beta-catenin and CD44. Oncotarget 2015, 6:33893-33911.
210. Fang B.A., Kovacevic Z., Park K.C., Kalinowski D.S., Jansson P.J., Lane D.J., Sahni S., Richardson D.R. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim. Biophys. Acta 2014, 1845:1-19.
211. Lu W.J., Chua M.S., Wei W., So S.K. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3beta and Nur77 to prevent beta-catenin degradation. Oncotarget 2015, 6:29847-29859.
212. Lui G.Y., Kovacevic Z., Richardson V., Merlot A.M., Kalinowski D.S., Richardson D.R. Targeting cancer by binding iron: dissecting cellular signaling pathways. Oncotarget 2015, 6:18748-18779.
213. Murakami Y., Hosoi F., Izumi H., Maruyama Y., Ureshino H., Watari K., Kohno K., Kuwano M., Ono M. Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2010, 396:376-381.
214. Liu W., Yue F., Zheng M., Merlot A., Bae D.H., Huang M., Lane D., Jansson P., Lui G.Y., Richardson V., Sahni S., Kalinowski D., Kovacevic Z., Richardson D.R. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget 2015, 6:8851-8874.
215. Jin R., Liu W., Menezes S., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of beta-catenin through mechanisms involving FRAT1 and PAK4. J. Cell Sci. 2014, 127:3116-3130.
216. Dixon K.M., Lui G.Y., Kovacevic Z., Zhang D., Yao M., Chen Z., Dong Q., Assinder S.J., Richardson D.R. Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br. J. Cancer 2013, 108:409-419.
217. Chen Z., Zhang D., Yue F., Zheng M., Kovacevic Z., Richardson D.R. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 2012, 287:17016-17028.
218. Kovacevic Z., Chikhani S., Lui G.Y., Sivagurunathan S., Richardson D.R. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 2013, 18:874-887.
219. Sun J., Zhang D., Zheng Y., Zhao Q., Zheng M., Kovacevic Z., Richardson D.R. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol. Pharmacol. 2013, 83:454-469.
220. Kovacevic Z., Menezes S.V., Sahni S., Kalinowski D.S., Bae D.H., Lane D.J., Richardson D.R. The metastasis suppressor, N-myc downstream regulated gene-(NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. J. Biol. Chem. 2016, 291:1029-1052.
221. Goodman V.L., Brewer G.J., Merajver S.D. Copper deficiency as an anti-cancer strategy. Endocr. Relat. Cancer 2004, 11:255-263.
222. Gupte A., Mumper R.J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat. Rev. 2009, 35:32-46.
223. Kaiafa G.D., Saouli Z., Diamantidis M.D., Kontoninas Z., Voulgaridou V., Raptaki M., Arampatzi S., Chatzidimitriou M., Perifanis V. Copper levels in patients with hematological malignancies. Eur. J. Intern. Med. 2012, 23:738-741.
224. Nasulewicz A., Mazur A., Opolski A. Role of copper in tumour angiogenesis-clinical implications. J. Trace Elem. Med. Biol. 2004, 18:1-8.
225. Majumder S., Chatterjee S., Pal S., Biswas J., Efferth T., Choudhuri S.K. The role of copper in drug-resistant murine and human tumors. Biometals 2009, 22:377-384.
226. Linder M.C., Moor J.R., Wright K. Ceruloplasmin assays in diagnosis and treatment of human lung, breast, and gastrointestinal cancers. J. Natl. Cancer Inst. 1981, 67:263-275.
227. Senra Varela A., Lopez Saez J.J., Quintela Senra D. Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett. 1997, 121:139-145.
228. MacDonald G., Nalvarte I., Smirnova T., Vecchi M., Aceto N., Dolemeyer A., Frei A., Lienhard S., Wyckoff J., Hess D., Seebacher J., Keusch J.J., Gut H., Salaun D., Mazzarol G., Disalvatore D., Bentires-Alj M., Di Fiore P.P., Badache A., Hynes N.E. Memo is a copper-dependent redox protein with an essential role in migration and metastasis. Sci. Signal. 2014, 7. (ra56).
229. Harris E.D. A requirement for copper in angiogenesis. Nutr. Rev. 2004, 62:60-64.
230. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
231. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143:401-409.
232. Lowndes S.A., Harris A.L. The role of copper in tumour angiogenesis. J. Mammary Gland Biol. Neoplasia 2005, 10:299-310.
233. Sen C.K., Khanna S., Venojarvi M., Trikha P., Ellison E.C., Hunt T.K., Roy S. Copper-induced vascular endothelial growth factor expression and wound healing. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H1821-H1827.
234. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
235. Martin F., Linden T., Katschinski D.M., Oehme F., Flamme I., Mukhopadhyay C.K., Eckhardt K., Troger J., Barth S., Camenisch G., Wenger R.H. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 2005, 105:4613-4619.
236. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
237. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 42:267-281.
238. Richardson D.R. Potential of iron chelators as effective antiproliferative agents. Can. J. Physiol. Pharmacol. 1997, 75:1164-1180.
239. Buss J.L., Torti F.M., Torti S.V. The role of iron chelation in cancer therapy. Curr. Med. Chem. 2003, 10:1021-1034.
240. Brewer G.J. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discov. Today 2005, 10:1103-1109.
241. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 2003, 9:2593-2613.
242. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. 1956, 21:487-495.
243. Wong C., Richardson D.R. Beta-thalassaemia: emergence of new and improved iron chelators for treatment. Int. J. Biochem. Cell Biol. 2003, 35:1144-1149.
244. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14901-14906.
245. Richardson D.R., Ponka P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am. J. Hematol. 1998, 58:299-305.
246. Donfrancesco A., Deb G., Dominici C., Pileggi D., Castello M.A., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990, 50:4929-4930.
247. Blatt J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 1994, 14:2109-2112.
248. Porter H. Copper excretion in the urine of normal individuals and of patients with hepatolenticular degeneration (Wilson's disease). Arch. Biochem. Biophys. 1951, 31:262-265.
249. Brewer G.J., Yuzbasiyan-Gurkan V., Young A.B. Treatment of Wilson's disease. Semin. Neurol. 1987, 7:209-220.
250. Brewer G.J. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Metallomics 2009, 1:199-206.
251. Brewer G.J., Dick R.D., Johnson V., Wang Y., Yuzbasiyan-Gurkan V., Kluin K., Fink J.K., Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. initial therapy in 17 neurologically affected patients. Arch. Neurol. 1994, 51:545-554.
252. Pan Q., Kleer C.G., van Golen K.L., Irani J., Bottema K.M., Bias C., De Carvalho M., Mesri E.A., Robins D.M., Dick R.D., Brewer G.J., Merajver S.D. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002, 62:4854-4859.
253. Brem S.S., Zagzag D., Tsanaclis A.M., Gately S., Elkouby M.P., Brien S.E. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 1990, 137:1121-1142.
254. Redman B.G., Esper P., Pan Q., Dunn R.L., Hussain H.K., Chenevert T., Brewer G.J., Merajver S.D. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer Res. 2003, 9:1666-1672.
255. Ceci A., Felisi M., De Sanctis V., De Mattia D. Pharmacotherapy of iron overload in thalassaemic patients. Expert. Opin. Pharmacother. 2003, 4:1763-1774.
256. Brittenham G.M. Iron chelators and iron toxicity. Alcohol 2003, 30:151-158.
257. Hershko C., Abrahamov A., Konijn A.M., Breuer W., Cabantchik I.Z., Pootrakul P., Link G. Objectives and methods of iron chelation therapy. Bioinorg. Chem. Appl. 2003, 151-168.
258. Selig R.A., White L., Gramacho C., Sterling-Levis K., Fraser I.W., Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 1998, 58:473-478.
259. Donfrancesco A., De Bernardi B., Carli M., Mancini A., Nigro M., De Sio L., Casale F., Bagnulo S., Helson L., Deb G. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Eur. J. Cancer 1995, 31A:612-615.
260. Estrov Z., Tawa A., Wang X.H., Dube I.D., Sulh H., Cohen A., Gelfand E.W., Freedman M.H. In viitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987, 69:757-761.
261. Blatt J., Taylor S.R., Stitely S. Mechanism of antineuroblastoma activity of deferoxamine in vitro. J. Lab. Clin. Med. 1988, 112:433-436.
262. Blatt J., Stitely S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res. 1987, 47:1749-1750.
263. Sartorelli A.C., Booth B.A. Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 1967, 27:1614-1619.
264. Antholine W., Knight J., Whelan H., Petering D.H. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol. Pharmacol. 1977, 13:89-98.
265. Finch R.A., Liu M.C., Grill S.P., Rose W.C., Loomis R., Vasquez K.M., Cheng Y.C., Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59:983-991.
266. Sartorelli A.C., Agrawal K.C., Tsiftsoglou A.S., Moore E.C. Characterization of the biochemical mechanism of action of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enzym. Regul. 1976, 15:117-139.
267. Shao J., Zhou B., Di Bilio A.J., Zhu L., Wang T., Qi C., Shih J., Yen Y. A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther. 2006, 5:586-592.
268. Chaston T.B., Lovejoy D.B., Watts R.N., Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9:402-414.
269. Shao J., Zhou B., Zhu L., Qiu W., Yuan Y.C., Xi B., Yen Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 2004, 64:1-6.
270. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000, 404:42-49.
271. Myers J.M., Antholine W.E., Zielonka J., Myers C.R. The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress. Toxicol. Lett. 2011, 201:130-136.
272. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 2001, 31:1287-1312.
273. Cory J.G., Cory A.H., Rappa G., Lorico A., Liu M.C., Lin T.S., Sartorelli A.C. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 1994, 48:335-344.
274. Finch R.A., Liu M.C., Cory A.H., Cory J.G., Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzym. Regul. 1999, 39:3-12.
275. Knox J.J., Hotte S.J., Kollmannsberger C., Winquist E., Fisher B., Eisenhauer E.A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: A trial of the national cancer institute of Canada clinical trials group (NCIC IND.161). Investig. New Drugs 2007, 25:471-477.
276. Ma B., Goh B.C., Tan E.H., Lam K.C., Soo R., Leong S.S., Wang L.Z., Mo F., Chan A.T., Zee B., Mok T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investig. New Drugs 2008, 26:169-173.
277. Wadler S., Makower D., Clairmont C., Lambert P., Fehn K., Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncol. 2004, 22:1553-1563.
278. Foltz L.M., Dalal B.I., Wadsworth L.D., Broady R., Chi K., Eisenhauer E., Kobayashi K., Kollmannsburger C. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am. J. Hematol. 2006, 81:210-211.
279. Quach P., Gutierrez E., Basha M.T., Kalinowski D.S., Sharpe P.C., Lovejoy D.B., Bernhardt P.V., Jansson P.J., Richardson D.R. Methemoglobin formation by 3-AP, Dp44mT and other anti-cancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect. Mol. Pharmacol. 2012, 82:105-114.
280. Yen Y., Margolin K., Doroshow J., Fishman M., Johnson B., Clairmont C., Sullivan D., Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 2004, 54:331-342.
281. Ocean A.J., Christos P., Sparano J.A., Matulich D., Kaubish A., Siegel A., Sung M., Ward M.M., Hamel N., Espinoza-Delgado I., Yen Y., Lane M.E. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother. Pharmacol. 2010, 68:379-388.
282. Nutting C.M., van Herpen C.M., Miah A.B., Bhide S.A., Machiels J.P., Buter J., Kelly C., de Raucourt D., Harrington K.J. Phase II study of 3-AP triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 2009, 20:1275-1279.
283. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood 2004, 104:1450-1458.
284. Richardson D.R., Tran E.H., Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86:4295-4306.
285. Baker E., Richardson D., Gross S., Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992, 15:492-501.
286. Darnell G., Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999, 94:781-792.
287. Becker E.M., Lovejoy D.B., Greer J.M., Watts R., Richardson D.R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 2003, 138:819-830.
288. Lovejoy D.B., Richardson D.R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002, 100:666-676.
289. Noulsri E., Richardson D.R., Lerdwana S., Fucharoen S., Yamagishi T., Kalinowski D.S., Pattanapanyasat K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am. J. Hematol. 2009, 84:170-176.
290. Rao V.A., Klein S.R., Agama K.K., Toyoda E., Adachi N., Pommier Y., Shacter E.B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009, 69:948-957.
291. Merlot A.M., Pantarat N., Menezes S.V., Sahni S., Richardson D.R., Kalinowski D.S. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol. Pharmacol. 2013, 84:911-924.
292. Merlot A.M., Sahni S., Lane D.J., Fordham A.M., Pantarat N., Hibbs D.E., Richardson V., Doddareddy M.R., Ong J.A., Huang M.L., Richardson D.R., Kalinowski D.S. Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget 2015, 6:10374-10398.
293. Merlot A.M., Kalinowski D.S., Kovacevic Z., Jansson P.J., Lane D.J., Huang M.L., Sahni S., Richardson D.R. Making a case for albumin - a highly promising drug-delivery system. Future Med. Chem. 2015, 7:553-556.
294. Kovacevic Z., Chikhani S., Lovejoy D.B., Richardson D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011, 80:598-609.
295. Liu W., Xing F., Iiizumi-Gairani M., Okuda H., Watabe M., Pai S.K., Pandey P.R., Hirota S., Kobayashi A., Mo Y.Y., Fukuda K., Li Y., Watabe K. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 2012, 4:93-108.
296. Richardson D.R., Sharpe P.C., Lovejoy D.B., Senaratne D., Kalinowski D.S., Islam M., Bernhardt P.V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49:6510-6521.
297. Seebacher N.A., Lane D.J., Jansson P.J., Richardson D.R. Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-glycoprotein drug transporter. J. Biol. Chem. 2015, (In press, PMID: 26601947, DOI: 26601910.26601074/jbc.M26601115.26682450).
298. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994, 47:223-258.
299. Yamagishi T., Sahni S., Sharp D.M., Arvind A., Jansson P.J., Richardson D.R. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J. Biol. Chem. 2013, 288:31761-31771.
300. Zamora J.M., Beck W.T. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem. Pharmacol. 1986, 35:4303-4310.
301. Jansson P.J., Kalinowski D.S., Lane D.J., Kovacevic Z., Seebacher N.A., Fouani L., Sahni S., Merlot A.M., Richardson D.R. The renaissance of polypharmacology in the development of anti-cancer therapeutics: inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 2015, 100:255-260.
302. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
303. Lovejoy D.B., Sharp D.M., Seebacher N., Obeidy P., Prichard T., Stefani C., Basha M.T., Sharpe P.C., Jansson P.J., Kalinowski D.S., Bernhardt P.V., Richardson D.R. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 2012, 55:7230-7244.
304. Yu Y., Suryo Rahmanto Y., Obeidy P., Richardson D.R. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 2012, 165:148-166.
305. Odenike O.M., Larson R.A., Gajria D., Dolan M.E., Delaney S.M., Karrison T.G., Ratain M.J., Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investig. New Drugs 2008, 26:233-239.
306. Traynor A.M., Lee J.W., Bayer G.K., Tate J.M., Thomas S.P., Mazurczak M., Graham D.L., Kolesar J.M., Schiller J.H. A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group study 1503. Investig. New Drugs 2010, 28:91-97.
307. Harrington J.P., Hicks R.L. Spectral analysis of Fe(III)-complex reduction by hemoglobin: possible mechanisms of interaction. Int. J. Biochem. 1994, 26:1111-1117.
308. Basha M.T., Rodriguez C., Richardson D.R., Martinez M., Bernhardt P.V. Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia. J. Biol. Inorg. Chem. 2015, 19:349-357.
309. Sestak V., Stariat J., Cermanova J., Potuckova E., Chladek J., Roh J., Bures J., Jansova H., Prusa P., Sterba M., Micuda S., Simunek T., Kalinowski D.S., Richardson D.R., Kovarikova P. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget 2015, 6:42411-42428.
310. Kalinowski D.S., Yu Y., Sharpe P.C., Islam M., Liao Y.T., Lovejoy D.B., Kumar N., Bernhardt P.V., Richardson D.R. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 2007, 50:3716-3729.
311. Merlot A.M., Pantarat N., Lovejoy D.B., Kalinowski D.S., Richardson D.R. Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. Mol. Pharmacol. 2010, 78:675-684.
312. Kalinowski D.S., Sharpe P.C., Bernhardt P.V., Richardson D.R. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues. J. Med. Chem. 2007, 50:6212-6225.
313. Yu Y., Suryo Rahmanto Y., Hawkins C.L., Richardson D.R. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol. Pharmacol. 2011, 79:921-931.
314. Cater M.A., Pearson H.B., Wolyniec K., Klaver P., Bilandzic M., Paterson B.M., Bush A.I., Humbert P.O., La Fontaine S., Donnelly P.S., Haupt Y. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chem. Biol. 2013, 8:1621-1631.
315. French F.A., Freedlander B.L. Carcinostatic action of polycarbonyl compounds and their derivatives. I. 3-Ethoxy-2-ketobutyraldehyde and related compounds. Cancer Res. 1958, 18:172-175.
316. French F.A., Freedlander B.L. Carcinostatic action of polycarbonyl compounds and their derivatives. 4. Glyoxal bis(thiosemicarbazone) and derivatives. Cancer Res. 1958, 18:1290-1300.
317. Petering H.G., Buskirk H.H., Underwood G.E. The anti-tumor activity of 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) and related compounds. Cancer Res. 1964, 24:367-372.
318. Petering H.G., Buskirk H.H., Crim J.A. The effect of dietary mineral supplements of the rat on the antitumor activity of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res. 1967, 27:1115-1121.
319. Booth B.A., Sartorelli A.C. Synergistic interaction of kethoxal bis(thiosemicarbazone) and cupric ions in sarcoma 180. Nature 1966, 210:104-105.
320. Crim J.A., Petering H.G. The antitumor activity of Cu(II)KTS, the copper (II) chelate of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res. 1967, 27:1278-1285.
321. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J. Biol. Inorg. Chem. 2002, 7:249-259.
322. Minkel D.T., Saryan L.A., Petering D.H. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. Cancer Res. 1978, 38:124-129.
323. Blower P.J., Castle T.C., Cowley A.R., Dilworth J.R., Donnelly P.S., Labisbal E., Sowrey F.E., Teat S.J., Went M.J. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans. 2003, 4416-4425.
324. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 1997, 38:1155-1160.
325. Blower P.J., Dilworth J.R., Maurer R.I., Mullen G.D., Reynolds C.A., Zheng Y. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J. Inorg. Biochem. 2001, 85:15-22.
326. Maurer R.I., Blower P.J., Dilworth J.R., Reynolds C.A., Zheng Y., Mullen G.E. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J. Med. Chem. 2002, 45:1420-1431.
327. Donnelly P.S., Caragounis A., Du T., Laughton K.M., Volitakis I., Cherny R.A., Sharples R.A., Hill A.F., Li Q.X., Masters C.L., Barnham K.J., White A.R. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J. Biol. Chem. 2008, 283:4568-4577.
328. Crouch P.J., Hung L.W., Adlard P.A., Cortes M., Lal V., Filiz G., Perez K.A., Nurjono M., Caragounis A., Du T., Laughton K., Volitakis I., Bush A.I., Li Q.X., Masters C.L., Cappai R., Cherny R.A., Donnelly P.S., White A.R., Barnham K.J. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:381-386.
329. Bica L., Meyerowitz J., Parker S.J., Caragounis A., Du T., Paterson B.M., Barnham K.J., Crouch P.J., White A.R., Donnelly P.S. Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex. Biometals 2011, 24:117-133.
330. Gutierrez E., Richardson D.R., Jansson P.J. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J. Biol. Chem. 2014, 289:33568-33589.
331. Stefani C., Al-Eisawi Z., Jansson P.J., Kalinowski D.S., Richardson D.R. Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization. J. Inorg. Biochem. 2015, 152:20-37.